Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 7 of the 30 sources its claims cite were checked for support.
Abstract
BACKGROUND: mRNA with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels. METHODS: We conducted a phase 3, double-blind, randomized 52-week trial to evaluate the safety and effectiveness of volanesorsen in 66 patients with familial chylomicronemia syndrome. Patients were randomly assigned, in a 1:1 ratio, to receive volanesorsen or placebo. The primary end point was the percentage change in fasting triglyceride levels from baseline to 3 months. RESULTS: Patients receiving volanesorsen had a decrease in mean plasma apolipoprotein C-III levels from baseline of 25.7 mg per deciliter, corresponding to an 84% decrease at 3 months, whereas patients receiving placebo had an increase in mean plasma apolipoprotein C-III levels from baseline of 1.9 mg per deciliter, corresponding to a 6.1% increase (P<0.001). Patients receiving volanesorsen had a 77% decrease in mean triglyceride levels, corresponding to a mean decrease of 1712 mg per deciliter (19.3 mmol per liter) (95% confidence interval [CI], 1330 to 2094 mg per deciliter [15.0 to 23.6 mmol per liter]), whereas patients receiving placebo had an 18% increase in mean triglyceride levels, corresponding to an increase of 92.0 mg per deciliter (1.0 mmol per liter) (95% CI, -301.0 to 486 mg per deciliter [-3.4 to 5.5 mmol per liter]) (P<0.001). At 3 months, 77% of the patients in the volanesorsen group, as compared with 10% of patients in the placebo group, had triglyceride levels of less than 750 mg per deciliter (8.5 mmol per liter). A total of 20 of 33 patients who received volanesorsen had injection-site reactions, whereas none of the patients who received placebo had such reactions. No patients in the placebo group had platelet counts below 100,000 per microliter, whereas 15 of 33 patients in the volanesorsen group had such levels, including 2 who had levels below 25,000 per microliter. No patient had platelet counts below 50,000 per microliter after enhanced platelet-monitoring began. CONCLUSIONS: Volanesorsen lowered triglyceride levels to less than 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome. Thrombocytopenia and injection-site reactions were common adverse events. (Funded by Ionis Pharmaceuticals and Akcea Therapeutics; APPROACH Clinical Trials.gov number, NCT02211209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 15 Not checked · 60 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These data show that volanesorsenmediated lowering of apolipoprotein C-III effectively enhances clearance of triglyceride-rich lipoproteins in patients without LPL activity.27”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Discussion
What the sources say
- Partly supportedcites [27] sourceExperimental — accuracy not yet measured
The Introduction (p. n/a) states that volanesorsen 'dramatically lowered elevated plasma TG levels in patients who have genetic defects in LPL (familial chylomicronemia syndrome [FCS])' and that, despite the absence of a placebo control group, 'this finding suggests that ApoC-III impairs TG clearance predominantly in an LPL-independent fashion'; the Discussion adds that their mouse data are 'consistent with the recent observation that targeting of ApoC-III effectively reduces plasma TGs in LPL-deficient patients'. So the enhanced-clearance-in-LPL-deficient-patients reading is present, but the source hedges it as a suggestion inferred from TG lowering (clearance itself was measured only in mice) and explicitly flags the uncontrolled design; the Discussion also notes the FCS subjects had a mutated LPL with possible residual activity rather than a strict absence. The citing sentence's unhedged 'these data show ... effectively enhances clearance' therefore overstates what this source attributes to the trial. (LLM, conf=0.72)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Discussion
What the sources say
- Not checked yetcites [6] source
- Could not verifycites [21] sourceExperimental — accuracy not yet measured
Our copy of the NLA Part 2 recommendations contains no mention of volanesorsen, apolipoprotein C-III as a therapeutic target, or the APPROACH trial (searched: 'volanesorsen APPROACH trial apolipoprotein C-III familial chylomicronemia syndrome', 'apolipoprotein C-III antisense oligonucleotide new therapies', 'severe hypertriglyceridemia pancreatitis threshold'). The closest passages cover only established therapy for very high TG — the 'Dietary considerations for management of hypertriglyceridemia' and 'Targets of lifestyle therapies' sections set the pancreatitis-prevention goal at lowering TG to <500 mg/dL (noting chylomicronemia is often present at ≥750 mg/dL), and the 'Non-statin recommendations' / 'Fibrates' sections discuss fenofibrate and prescription omega-3s — so nothing here speaks to the trial result attributed to this source. Our copy is also flagged as truncated, so the decisive text may be missing. (LLM, conf=0.72)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
Our copy of the 2012 Endocrine Society guideline contains no mention of volanesorsen, the APPROACH trial, or an antisense apoC-III oligonucleotide (searched: 'volanesorsen APPROACH trial apolipoprotein C-III antisense', 'antisense oligonucleotide apoC-III inhibitor', '750 mg/dl triglyceride threshold'); apoC-III appears only in pathophysiology/kinetics references. Nor does it give a 750-880 mg/dl pancreatitis threshold: the Chylomicronemia syndrome section states pancreatitis risk 'markedly increases with very severe triglyceride levels above 2000 mg/dl' and 'can be prevented by maintaining triglyceride levels below 1000 mg/dl', and the Fibrates section sets a treatment goal of <1000 mg/dl. The trial result attributed here is therefore not addressed by this source at all (the guideline predates the APPROACH trial), so the claim cannot be checked against it. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“findings that support the hypothesis that apolipoprotein C-III also inhibits an LPL-independent pathway of triglyceride-rich lipoprotein clearance.16”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > F
What the sources say
- Supportedcites [16] source
The Discussion says the study's findings suggest that APOC3 regulates triglyceride-rich lipoprotein metabolism through LPL-independent pathways. The Figure 2 caption states more specifically that APOC3 has an inhibitory role in that pathway, matching the citing sentence's hypothesis. (LLM, conf=0.94)
hedgedstates a causen = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three other patients with lesser grades (grade 1 or 2) of decreased platelet counts were withdrawn from the trial because of concerns on the part of the site investigators.”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fourteen patients assigned to volanesorsen, as compared with 2 patients assigned to placebo, did not complete the 52-week trial”
- Also stated in: § 541 · plain
“Fourteen patients in the volanesorsen group discontinued the trial: 9 because of adverse events that occurred during treatment (including 5 who had decreases in platelet counts and 4 because of other drug-related side effects), and 5 primarily because of issues related to requirements of the protocol.”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 541 · plain
22 more claims
Create a free account to see all 79 claims and to verify the 23 references still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 38
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our findings are consistent with the observations that LDL cholesterol levels are typically very low (<20 mg per deciliter [0.52 mmol per liter]) and total apolipoprotein B levels are within the low-to-normal range in persons with familial chylomicronemia syndrome. 25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous trial involving patients with familial chylomicronemia syndrome, the administration of volanesorsen at a weekly dose of 300 mg per deciliter over a 3-month period was accompanied by reductions in apolipoprotein C-III and triglyceride levels of 84% and 77%, respectively, 25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While APPROACH was not powered to detect clinical endpoints, exploratory analyses showed a meaningful reduction in pancreatitis episodes among patients who achieved sustained TG levels below 500 mg/dL— considered by some to be a threshold for pancreatitis risk [44].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“its safety profile, particularly the high incidence of thrombocytopenia, has limited broader clinical adoption [115]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [115]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduced platelet counts below 100 000 per microliter was a common adverse event in the volanesorsen group (15 of 33 patients, two patients with levels < 25 000 per microliter).74”
From Clinical review on triglycerides (2020) · cites this paper as [74]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Abstract
“15 of 33 patients in the volanesorsen group had such levels”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
“confirmed nadir levels below 100,000 per microliter were observed in 16 patients (48%) who received volanesorsen”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“1933 mg per deciliter [22.5 mmol per liter]”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Secondary Efficacy End Points
Reported 22.5 · recomputed 21.82357
Citations
Cites
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationTargeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationIssues in Hypertriglyceridemic Pancreatitis: An Update
Scherer, J., Singh, V. P., Pitchumoni, C. S., & Yadav, D. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000436438.60145.5a · Cited by 475
Current knowledge of hypertriglyceridemic pancreatitis
Valdivielso, P., Ramírez-Bueno, A., & Ewald, N. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.08.008 · Cited by 439
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
Biochemistry and pathophysiology of intravascular and intracellular lipolysis
Young, S. G., & Zechner, R. (2013) · Genes & Development · doi:10.1101/gad.209296.112 · Cited by 348
Research works printed but not linked: 1
- Brunzell JD Deeb SS. Familial lipoprotein lipase deficiency apo CII deficiency and hepatic lipase deficiency. In: Scriver CR Beaudet AL Sly WS et al. eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill 2000:2789-816.
Cited by
Items 401–500 of 673
Fibrates : Do They Still Have a Role in Therapy in 2025?
Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4
“Similarly, APOC3 antisense therapies with volanesorsen, olezarsen or plozasiran achieve triglyceride reductions exceeding 70% in patients with severe hypertriglyceridaemia [34–36 ].”
Nucleic Acid–Based Therapies — The Next Frontier in Treating Dyslipidemias
Hegele, R. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.01.026 · Cited by 5
Simultaneous Quantification of Apolipoprotein C-III O-Glycoforms by Protein-MRM
Kim, H., Cheon, D. H., Yang, W. S., & Baek, J. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00490 · Cited by 5
RNA therapeutics for metabolic disorders
Vu, T.-D., Lin, S., Wu, C., & Chu, D. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.014 · Cited by 5
Biopharmaceuticals: A review of their development and contribution to healthcare
Liew, K. B., Lee, S.-K., Ming, L. C., Uddin, A. B. M. H., Sarker, M. Z. I., Chew, Y.-L., & Kee, P. E. (2023) · Biomedical and Biopharmaceutical Research · doi:10.19277/bbr.20.2.321 · Cited by 10
Bian, X., Zhang, Y., Shao, M., Li, J., Ge, J., Li, Z., Peng, H. Y., & Zhang, M. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001361 · Cited by 6
“ApoC-III impedes the hydrolysis and clearance of TRL from the bloodstream by inhibiting lipoprotein lipase (LPL) and hepatic lipase [46].”
BackgroundHeath, O., Allender, B., Smith, J. D., Savva, E., Spencer, L., Bannister, E. G., Brown, N. J., Evans, M. S., Kiss, S., Rozen, T. H., et al. (2024) · JIMD Reports · doi:10.1002/jmd2.12434 · Cited by 6
“35,36 Furthermore, a recent meta-analysis reported a reduction in the incidence of acute pancreatitis among patients with severe hypertriglyceridemia treated with Volanesorsen.”
BackgroundPan, Z., Zaman, M. A., Kalsoom, S., & Zhang, Y. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2423724 · Cited by 4
“Triglyceride levels were significantly reduced (71.2% and 77%, respectively) [28].”
InfluentialFujiki, K., Kakisawa, Y., Mahmoud, E. M., & Ueno, Y. (2025) · Molecules · doi:10.3390/molecules30030581 · Cited by 4
Vlacho, B., Julve, J., Genua, I., Fernández‐Camins, B., Real, J., Franch‐Nadal, J., Mauricio, D., & Ortega, E. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.195 · Cited by 6
Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline
Xu, J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211053489 · Cited by 4
“One patient in the volanesorsen group had a platelet count of < 50,000/μL(65) Mechanisms underlying the decline in platelets remain unclear.(60) The authors concluded that while volanesorsen effectively reduced TG levels, its adverse effect profile may preclude its use.”
BackgroundInfluentialUncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.04.002 · Cited by 9
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Zhou, Y., Sakamoto, S., & Ueno, Y. (2022) · Molecules · doi:10.3390/molecules27217384 · Cited by 4
“In this study, we focus on a special formation, named “gapmer”, composed of chemically modified wing regions for high RNA-binding affinity and robust nuclease resistance, and a DNA-based gap region for efficient RNase H-dependent antisense mechanism [3,6,7].”
BackgroundUpdate on management of paediatric dyslipidaemia
Bansal, N., Kumar, S., & Brar, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000794 · Cited by 4
Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
Isaac, R. H., Devia, D. G., Mendivil, C. O., & Chapman, E. (2023) · Frontiers in Allergy · doi:10.3389/falgy.2023.1201807 · Cited by 4
“Hypersensitivity to volanesorsen has not been previously reported, and hence, no desensitization protocol has been established (5, 6).”
BackgroundLarouche, M., Brisson, D., Morissette, M.-C., & Gaudet, D. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02743-0 · Cited by 4
“No other discontinuations were due to platelet decrease in this study (6).”
BackgroundSelf-citationInvestigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
“The cohort description and results of APPROACH have been published [96,97].”
BackgroundPedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.12.001 · Cited by 7
Hypertriglycéridémies majeures : diagnostic et prise en charge
Charrière, S. (2021) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2020.12.002 · Cited by 5
Incidental finding of lipaemia retinalis on diabetic retinal screening
Kempegowda, P., Chen, W., Melson, E., Leong, A., Amrelia, P., & Syed, A. (2021) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-21-0051 · Cited by 4
Dondalska, A., Pålsson, S. A., & Spetz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314593 · Cited by 4
den Hollander, B., Brands, M. M. M. G., Nijhuis, I. J. M., van Troostwijk, L. J. A. E. D., van Essen, P., Hofsteenge, G. H., Koot, B. G. P., Müller, A. R., Tseng, L. A., Stroes, E. S. G., et al. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108347 · Cited by 4
Self-citationLipoprotein Lipase Deficiency: Diet is the Key!
Patil, K., & Gupta, N. (2021) · The Indian Journal of Pediatrics · doi:10.1007/s12098-020-03640-1 · Cited by 4
“Other newer treatment modalities include a second-generation antisense oligonucleotide inhibitor of apolipoprotein C-III (APOC3), volanesorsen which leads to a reduction in hepatic production of APOC3, thereby decreasing hypertriglyceridemia [6].”
BackgroundAngiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management
Ying, Q., Chan, D. C., & Watts, G. F. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000747 · Cited by 4
Pancreatitis Secondary to Dyslipidemia: An Understudied Condition
Jacobs, T. H., Wayne, C. D., Sajankila, N., & Narayanan, S. (2024) · Lipidology · doi:10.3390/lipidology1020009 · Cited by 3
“…effect in DL-associated pancreatitis, such as the antisense oligonucleotides Volanesorsen (which blocks apoC-III synthesis by targeting APOC3 mRNA) and Vupanorsen (which targets the angiopoietin-like protein 3 (ANGPTL3) mRNA) or the monoclonal antibody Evinacumab (targets ANGPTL3) [112,133–139].”
Apolipoprotein C3 Promotes Angiogenesis in an Inflammatory Mouse Model of Peripheral Artery Disease
Thomas, J., Bamhare, P. M., Mulangala, J., Bursill, C. A., Nicholls, S. J., Bartolo, B. A. D., & Bubb, K. J. (2025) · The FASEB Journal · doi:10.1096/fj.202502155r · Cited by 3
“Inflammatory stimuli can trigger nuclear factor kappa- light- chain-enhancer of activated B cells (NF-κB)- dependent VEGF expression [12], potentially driving pathological angiogenesis.”
A Workflow for Transcriptome-Wide Assessment of Antisense Oligonucleotide Selectivity
Damle, S. S., Watt, A., Kuntz, S., Crutchfield, A., Carlborg, E., Webb, J., Quirk, C., Relić, Đ., Donovan, S., Hart, C. E., et al. (2025) · Nucleic Acid Therapeutics · doi:10.1177/21593337251378141 · Cited by 3
Lipid lowering therapies in chronic kidney disease: A call to action
Ruiz, J. M., Arroyo, D., de Cos, M., Fernández, M. R., Sánchez-Álvarez, E., Bores, P. G., Hernández, J. L., & Corral, P. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120563 · Cited by 4
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
“Moreover, a reduction in risk for AP would be expected to correlate with the marked reduction in TG levels observed in these patients [36].”
Self-citationLi, Y., Zhou, X., Wen, Y., Huang, Q., Yang, X., Mukherjee, R., Sutton, R., Liu, T., Cai, W., & Huang, W. (2026) · Biomedicines · doi:10.3390/biomedicines14071574 · Cited by 3
“Volanesorsen, a first-generation APOC3 antisense oligonucleotide, substantially reduced TG levels in patients with FCS, but its use is limited by thrombocytopenia and injection-site reactions [146].”
Theodoropoulos, P., Fanaropoulou, N. M., & Manessis, A. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.08.006 · Cited by 3
Kršek, A., Batičić, L., & Tokmadžić, V. S. (2024) · Cardiogenetics · doi:10.3390/cardiogenetics14030012 · Cited by 5
“This makes it possible to administer less frequently and at lower levels to obtain the desired results [51–54].”
Nucleic Acid Drugs in Radiotherapy
Yang, Y., Cai, Y., Deng, K., Xiao, Y., Liu, X., & Du, Z. H. (2025) · ChemBioChem · doi:10.1002/cbic.202400854 · Cited by 4
Zambon, A., Gentile, L., Galimberti, F., Manzato, E., Giaccari, A., Sesti, G., Belfiore, A., Norata, G. D., Temporelli, P. L., Frulloni, L., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104214 · Cited by 3
Self-citationOgunniyi, K. E., Aghasili, C. C., Akinmoju, O. D., Olaiya, V. O., Abib, O. M., Odueke, A., Popoola, H. A., Onyenokwe, V., Onaolapo, D., Usman, A.-A. M., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00762-9 · Cited by 3
ERUPTIVE XANTHOMA: A MARKER OF HYPERTRIGLYCERIDEMIA
Çakmak, R., Çaklılı, Ö. T., & Selçukbiricik, Ö. S. (2021) · Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi · doi:10.26650/iuitfd.2021.844088 · Cited by 3
Calcaterra, I. L., Santoro, R., Vitelli, N., Cirillo, F., D’Errico, G., Guerrino, C., Cardiero, G., Taranto, M. D. D., Fortunato, G., Iannuzzo, G., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092017 · Cited by 3
“For this reason, the patients were treated with immunoglobulins and steroids with close platelet monitoring, accompanied by a dose reduction, and achieved complete recovery [10].”
BackgroundHow to handle hypertriglyceridaemia in acute pancreatitis – Still a vote for conservatives?
Eriksson, M., & Angelin, B. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12971 · Cited by 3
Nuevos tratamientos en la hipertrigliceridemia y en la hiperquilomicronemia
García-Díaz, J. D. D. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2019.11.003 · Cited by 3
Kishimura, T., Tomori, T., MASAKI, Y., & Seio, K. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127779 · Cited by 3
A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 4
Tratamiento de la quilomicronemia
Hermoso, A. N., & Valdivielso, P. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.01.004 · Cited by 3
Molina, D. I., Villar-Moya, R., Villar-Henríquez, M., & Murillo-Aranguren, M. C. (2021) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m21000053 · Cited by 7
Lipidtherapie bei Patienten mit Diabetes mellitus
Parhofer, K. G., Birkenfeld, A. L., Krone, W., Lehrke, M., Marx, N., Merkel, M., Schütt, K. S., Zirlik, A., & Müller‐Wieland, D. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00905-5 · Cited by 4
Sasmana, I. G. A. P., Rahadi, P. N. K., Devy, A. A. T., Dewi, P. A. S., Supadmanaba, I. G. P., & Wihandani, D. M. (2023) · Indonesia Journal of Biomedical Science · doi:10.15562/ijbs.v17i1.455 · Cited by 8
Significance of traditional herbal medicine for dyslipidemia.
Kang, Y., Kim, Y.-J., & Kim, K. (2023) · PubMed Central · Cited by 15
PROGRESS OF OLIGONUCLEOTIDE THERAPEUTICS TARGET TO RNA
Pan, Y., Zhou, X., & Yang, Z. (2022) · Wiley eBooks · doi:10.1002/9781119692799.ch11 · Cited by 6
From Bench to Bedside: Current Developments in RNA-Based Therapies for Treatment of Hyperlipidemia
Zhou, Y., & Chen, C. (2022) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.v1i1.141 · Cited by 3
“The APPROACH trial, a phase III trial in patients with familial chylomicronemia, showed that the triglyceride levels in 77% of participants treated with Volanesorsen were less than 750 mg per deciliter [29].”
MethodReducing the Risk of Pancreatitis by Inhibiting APOC3
Stitziel, N. O. (2025) · New England Journal of Medicine · doi:10.1056/nejme2411605 · Cited by 5
Rehman, A., Rajdeep, D., Mohnkern, J. D., & Lin, J. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09846-1 · Cited by 2
Klose, G., Gouni‐Berthold, I., & März, W. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01524-y · Cited by 2
Bedoya, C., Thomas, R., Bjarvin, A., Ji, W., Samara, H., Tai, J., Green, L., Frost, P. H., Malloy, M. J., Pullinger, C. R., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.10.004 · Cited by 2
Antisense Oligonucleotides (ASOs)
Tosar, J. P. (2024) · Topics in medicinal chemistry · doi:10.1007/7355_2024_170 · Cited by 3
Tramontano, D., Martino, M. D., Baratta, F., Costanzo, A. D., Cocomello, N., Commodari, D., Bini, S., Minicocci, I., Arca, M., & D’Erasmo, L. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.004 · Cited by 3
Self-citationRomán-Gonzaléz, A., Arroyo-Ripoll, O. F., Ramos, A. F. G., Monsalve, C., Daguer, S., Barón, F., Berg, G. A., Fariña, G., Zuluaga, N. A., Torres, A. C. F., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.006 · Cited by 3
D’Erasmo, L., Tramontano, D., & Arca, M. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000941 · Cited by 3
Self-citationZuin, M., & Bilato, C. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04234-5 · Cited by 2
Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis
Schrottmaier, W. C., Kral-Pointner, J. B., Mußbacher, M., Salzmann, M., Hochreiter, B., Pirabe, A., Reiter, T., Badrnya, S., Schmid, J. A., Volf, I., et al. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.01.004 · Cited by 3
“Antisense oligo-nucleotides targeting apoC3 messenger RNA efficiently reduce triglyceride and cholesterol levels, and the first drug of this class has been approved for treatment of familial chylomicronemia syndrome [50,51].”
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 3
Katzmann, J. L., & Laufs, U. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01390-7 · Cited by 2
“…cardiovascular benefits in patients on statin or with statin intolerance by further reducing LDL-C. to 77% ↓ in FCS Phase 3 trials completed [49, 50] Olezarsen Antisense oligonucleotide, s. c. Treatment with these agents allowed for the achievement of lower LDL-C concentrations than…”
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
Zadeh, S. S. T., Toth, P. P., & Banach, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789019 · Cited by 2
“Long-term follow-up indicated sustained TG reduction, though somewhat attenuated over time, with injection site reactions, thrombocytopenia, and fatigue as the most frequent adverse events (Jones et al., 2023; Witztum et al., 2019).”
Expanding the toolbox: Emerging antisense oligonucleotide mechanisms for modulating gene expression
Trew, I., Wilton, S. D., Cale, J. M., & Aung-Htut, M. T. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102953 · Cited by 2
ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome
Yin, E. B., Wanat, M. A., & Wang, E. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261452675 · Cited by 2
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 4
“414 To overcome these limitations, Olezarsen, a next-generation ASO with enhanced liver-targeting properties conferred by a GalNAc moiety, was developed.”
Tani, H. (2026) · IUBMB Life · doi:10.1002/iub.70122 · Cited by 2
“The hepatic gapmers mipomersen, inot-ersen, and volanesorsen mark the opposite, stable-target end: intermediate- half-life mRNAs giving durable knockdown with infrequent dosing, paced by the persistent ASO rather than target turnover [49–51].”
Shah, M. A., Sharma, A., Ayyad, M., Swartz, E., Jafrani, D., & Gala, D. (2024) · Cureus · doi:10.7759/cureus.67091 · Cited by 5
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Ahmad, M., & Hegele, R. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00768-0 · Cited by 5
“Two patients taking volanesorsen had platelet counts 25,000/ mL. Platelet counts recovered after drug discontinuation and enhanced platelet monitoring during the trial helped prevent severe thrombocytopenia [62].”
Pechetty, R., Rao, P. S., Deb, T., Shekar, C., & Deepthi, K. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_55_2025 · Cited by 2
Fricke, U., Hein, L., & Schwabe, U. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_2 · Cited by 5
Gene Silencing Therapeutics in Cardiology: A Review Article
Jay, P. Y., Maier, M. A., Saltonstall, L., Duarte, L., Antonino, I., & Vest, J. (2021) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20200306 · Cited by 3
Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome
Górecka, W., Berezovska, D., Mrozińska, M., Nowicka, G., & Czerwińska, M. E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060768 · Cited by 2
“For patients in the placebo group, a mean increase of 18% in TG concentration was observed [175].”
Bajaj, A., Oral, E. A., Brown, A. S., Gaudet, D., Alexander, V. J., Karwatowska‐Prokopczuk, E., & Baum, S. J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101352 · Cited by 2
“Ole-zarsen differs from volanesorsen by the inclusion of 3 GalNAc residues that bind to asialoglycoprotein receptors on hepatocytes, permitting ASO delivery to hepatocyte nuclei where APOC3 mRNA is generated and allowing for greater potency and less systemic exposure [16,17,54].”
InfluentialSelf-citationClinical strategies for reducing cholesterol levels
Lardinois, C. K., & Karr, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00027-4 · Cited by 2
RNA therapies for cardiovascular disease
Laina, A., Vlachogiannis, N. I., Stamatelopoulos, K. S., & Stellos, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822546-2.00003-4 · Cited by 2
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Self-citationValéro, R. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.013 · Cited by 2
J-shaped association between circulating apoC-III and cardiovascular mortality
Silbernagel, G., Scharnagl, H., Kleber, M. E., Hoffmann, M. M., Delgado, G. E., Stojaković, T., Gary, T., Zeng, L., Ritsch, A., Zewinger, S., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa169 · Cited by 2
Working towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
Self-citationTünnemann-Tarr, A., Scharnagl, H., Katzmann, J. L., Stürzebecher, P. E., & Laufs, U. (2021) · Medicine · doi:10.1097/md.0000000000027573 · Cited by 2
“allows mRNA degradation prevents the translation of the apoCIII mRNA and lowers triglycerides.([19]) In our patient, volanesorsen rapidly reduced apoCIII serum concentrations and serum triglyceride concentration by 90%.”
Elbahloul, M. A., Gamal, A., Maihoub, O., Elbaz Hassan, M. M., Attia, M. K., Salah, A. M., Elboraay, T., Awad, A. K., Akoum, A., Elazab, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70717 · Cited by 1
“Furthermore, their impact on the clinically pivotal outcome of acute pancreatitis is not yet clearly defined [7, 19, 20].”
Hypertriglyzeridämie mit Pankreatitis
Klingel, R., Heibges, A., & Fassbender, C. (2021) · Dialyse aktuell · doi:10.1055/a-1303-8379 · Cited by 1
Karwatowska‐Prokopczuk, E., Lu, L., Yang, J. M., Witztum, J. L., & Tsimikas, S. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02818-6 · Cited by 1
Self-citationTamoxifen- and Triptorelin-Induced Major Hypertriglyceridemia: A Case Report
Moussaoui, W., Lahmamssi, F.-Z., Aynaou, H., Salhi, H., & Ouahabi, H. E. (2024) · Cureus · doi:10.7759/cureus.53779 · Cited by 2
“Approach and compass studies have been shown to lower TGs and suppress the recurrence of acute pancreatitis [24,25].”
BackgroundLipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
Kalanj, J., Cobeljic, M., Ješić, M. D., Zdravković, V., Cvetković, M., Vukasinovic, N., Andjelković, M., & Rsovac, S. (2024) · BMC Pediatrics · doi:10.1186/s12887-024-05287-9 · Cited by 2
Pediatric Hypertriglyceridemia: Lipoprotein Metabolism, Etiology, and Management
Moriyama, H., & Ham, J. N. (2025) · Current Pediatrics Reports · doi:10.1007/s40124-025-00349-7 · Cited by 3
“The first of these medications, volanesoren, is an antisense oligonucleotide (ASO) against APOC3 [70].”
Арманович, А. А., Kaktursky, L. V., Urazova, O. I., Трофименко, А. И., Sukiasyan, L. M., Коган, Е. А., Демура, Т. А., & Вачиковна, П. Н. (2025) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2025-2-124-140 · Cited by 1
2717 Advances in therapeutic oligonucleotide chemistry
Jorge, A. F., Grijalvo, S., Aviñó, A. M., Fàbrega, C., & Eritja, R. (2025) · De Gruyter eBooks · doi:10.1515/9783111425085-007 · Cited by 1
ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction
Holzer, M., Gruden, E., Ćurčić, S., Cvirn, G., & Marsche, G. (2025) · Cells · doi:10.3390/cells14181411 · Cited by 1
“Importantly, no significant thrombocytopenia has been reported with Olezarsen, whereas Volanesorsen has been associated with dose-dependent thrombocytopenia, necessitating close monitoring and treatment adjustments [10,11].”
InfluentialTwo Sides of Triglycerides in Atherogenesis: An Essential Contributor
Poznyak, A. V., Kozlov, S. G., Babayeva, G. A., Sukhorukov, V. N., & Orekhov, A. N. (2025) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468241291640 · Cited by 2
ESC-Leitlinien-Update 2025 zur Dyslipidämie
Hohneck, A., & Weingärtner, O. (2025) · Herz · doi:10.1007/s00059-025-05354-6 · Cited by 1
Meghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1
Dyslipidemias in Chronic Kidney Disease: Pathophysiology and Emerging Therapies
Capón, I. M., Lerma, E. V., Anandh, U., So, P. N., & Hassanein, M. (2026) · Indian Journal of Nephrology · doi:10.25259/ijn_711_2025 · Cited by 1
The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications
Bonanni, L., Cutolo, A., & Ferri, N. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07855-w · Cited by 2
“The management of severe hypertriglyceridemia is also revised, emphasizing the importance of a more structured approach and, when necessary, specific therapies to reduce both atherothrombotic risk and pancreatitis risk [7–9].”
Popiołek-Kalisz, J., & Sabouret, P. F. (2026) · Advances in Medical Sciences · doi:10.1016/j.advms.2026.02.006 · Cited by 1
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome
Hang, S., & Hegele, R. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2646166 · Cited by 2
“Unfortunately, due to a high incidence of severe thrombocytopenia, the treatment never received regulatory approval in North America, although it is approved in Europe for treatment of FCS [41].”
InfluentialZhu, Y., Yuan, R., Lu, Z., Zhang, Y., Kang, Z., Feng, X., Zhao, G., Sun, J., Guo, J., Yu, T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102653 · Cited by 2
Metadata
- Authors
- Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., Stroes, E. S. G., Bergeron, J., Soran, H., Civeira, F., Hemphill, L., Tsimikas, S., Blom, D. J., O’Dea, L., & Bruckert, E.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- From the Department of Medicine, University of California San Diego, La Jolla (J.L.W., S.T.), and Ionis Pharmaceuticals, Carlsbad (V.J.A., Q.Y., S.G.H., R.S.G., S.T.) — both in California; the Department of Medicine, Université de Montréal and ECOGENE 21, Chicoutimi, QC (D.G.), and the Department of Medicine and Laboratory Medicine, Centre Hospitalier Universitaire de Québec–University Laval, Quebec, QC (J.B.) — both in Canada; the Department of Medicine, Beth Israel Deaconess Medical Center (S.D.F....
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-08
- Volume
- 381
- Issue
- 6
- Pages
- 531-542
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2966503756
- Semantic Scholar
- 1b419fba1e6af00f305b1f8b0ee92c239fec7d40
- Cited by
- 669
- References
- 34
- Citations by year
- 2026: 88 · 2025: 112 · 2024: 112 · 2023: 77 · 2022: 95 · 2021: 91 · 2020: 79 · 2019: 14
- FWCI
- 50.23
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zaguan (University of Zaragoza Repository) (submittedVersion)
- Funders
- Akcea Therapeutics
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- volanesorsen, familial chylomicronemia syndrome, apolipoprotein C-III, triglyceride levels, antisense therapy, hypertriglyceridemia, injection site reactions, platelet count, treatment efficacy and safety, triglyceride lowering
- MeSH terms
- Adult, Aged, Analysis of Variance, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Platelet Count, RNA, Messenger, Thrombocytopenia, Triglycerides, Apolipoprotein C-III, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.